search
Back to results

The Olmsted NAFLD Epidemiology Study (TONES)

Primary Purpose

Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Magnetic Resonance Elastography
Blood draw
Liver biopsy
Fibro Scan
Sponsored by
Mayo Clinic
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Non-Alcoholic Fatty Liver Disease

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Olmsted County residents at the time of search
  • Age 18 or older
  • No personal history of NAFLD diagnosis (administrative codes)

Exclusion Criteria:

  • Alcohol in excess (more than 20 gm per week in women and 30 gm per week in men)
  • Currently pregnant
  • Have contraindications to MRI (MRI incompatible implanted devices, severe claustrophobia)

Sites / Locations

  • Mayo Clinic in RochesterRecruiting

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Subjects at risk for NAFLD

Arm Description

Adult Olmsted County residents identified as at risk for NAFLD will receive Magnetic Resonance Imaging (MRE,) blood tests,and possible biopsy.

Outcomes

Primary Outcome Measures

Prevalence of NAFLD and NASH in the population
Number of subjects with NAFLD and NASH determined by the MRE

Secondary Outcome Measures

Long-term health outcomes
Number of participants to experience the development of NAFLD, NASH, NASH cirrhosis complications, liver transplant, cardiovascular events, cancers or death

Full Information

First Posted
April 9, 2020
Last Updated
February 27, 2023
Sponsor
Mayo Clinic
search

1. Study Identification

Unique Protocol Identification Number
NCT04365855
Brief Title
The Olmsted NAFLD Epidemiology Study (TONES)
Official Title
The Olmsted NAFLD Epidemiology Study (TONES)
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 29, 2020 (Actual)
Primary Completion Date
June 2028 (Anticipated)
Study Completion Date
June 2028 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Mayo Clinic

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Researchers are assessing the prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) in the population and assembling a well-characterized cohort of adults with NAFLD and NASH to validate models of NAFLD diagnosis and determine long-term outcomes.
Detailed Description
Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common cause of chronic liver disease in the world and a major public health issue in the US. Recent information on the prevalence of NAFLD in general and Non-Alcoholic Steatohepatitis (NASH) with fibrosis in particular is very scarce. Such information is crucial for defining the epidemiology of NAFLD, identifying risk factors for advanced fibrosis and longitudinal outcomes. This study will enroll a random sample of adults from Olmsted County, Minnesota, to validate machine learning models for NAFLD diagnosis and disease severity. These data would be fundamental for the development of screening strategies in the community, which are urgently needed for early diagnosis of liver fibrosis and therapeutic interventions before cirrhosis develops.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
We will invite adult Olmsted County residents with research authorization, identified based on a random search of the Rochester Epidemiology Project database. We plan to accrue 800 participants. Based on literature estimates, approximately 25-30% of adults will be at risk for NAFLD due to overweight/obese status. Participants will undergo tests for NAFLD screening: blood tests, Magnetic Resonance Imaging/Elastography and electrocardiogram. Those identified with fatty liver will undergo Transient elastography and liver biopsy for disease severity assessment. These results will be used to validate a machine learning model of NAFLD diagnosis and liver disease severity which uses the participants clinical and laboratory data (noninvasive electronic health records). The cohort will be followed for 5 years, when they will return for repeat imaging and blood tests to monitor for incident NAFLD, liver disease progression and outcomes.
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
800 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Subjects at risk for NAFLD
Arm Type
Other
Arm Description
Adult Olmsted County residents identified as at risk for NAFLD will receive Magnetic Resonance Imaging (MRE,) blood tests,and possible biopsy.
Intervention Type
Diagnostic Test
Intervention Name(s)
Magnetic Resonance Elastography
Intervention Description
Combines MRI imaging with sound waves to create a visual map (elastogram) showing the stiffness of body tissues.
Intervention Type
Other
Intervention Name(s)
Blood draw
Intervention Description
Clinical blood tests with a focus on liver function parameters and diabetes
Intervention Type
Procedure
Intervention Name(s)
Liver biopsy
Intervention Description
If indicated per MRE results a biopsy will be taken of the liver.
Intervention Type
Procedure
Intervention Name(s)
Fibro Scan
Intervention Description
If indicated per MRE results a fibroscan will be performed of the liver.
Primary Outcome Measure Information:
Title
Prevalence of NAFLD and NASH in the population
Description
Number of subjects with NAFLD and NASH determined by the MRE
Time Frame
5 years
Secondary Outcome Measure Information:
Title
Long-term health outcomes
Description
Number of participants to experience the development of NAFLD, NASH, NASH cirrhosis complications, liver transplant, cardiovascular events, cancers or death
Time Frame
5 years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Olmsted County residents at the time of search Age 18 or older No personal history of NAFLD diagnosis (administrative codes) Exclusion Criteria: Alcohol in excess (more than 20 gm per week in women and 30 gm per week in men) Currently pregnant Have contraindications to MRI (MRI incompatible implanted devices, severe claustrophobia)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jessica L Olson
Phone
507-266-3995
Email
olson.jessica3@mayo.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
ALINA M ALLEN, MD
Organizational Affiliation
Mayo Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mayo Clinic in Rochester
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
No
Links:
URL
https://www.mayo.edu/research/clinical-trials
Description
Mayo Clinic Clinical Trials

Learn more about this trial

The Olmsted NAFLD Epidemiology Study (TONES)

We'll reach out to this number within 24 hrs